Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-15-0240-t
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Histone Deacetylase Inhibitors in Multiple Myeloma

Hematology Reports
Hematology
2009English

Therapeutic Strategies to Enhance the Anticancer Efficacy of Histone Deacetylase Inhibitors

Journal of Biomedicine and Biotechnology
2011English

New Insights Into the Treatment of Multiple Myeloma With Histone Deacetylase Inhibitors

Current Pharmaceutical Design
Drug DiscoveryPharmacology
2012English

Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat

Pharmacotherapy
Pharmacology
2015English

Inhibitors of Histone-Deacetylase

Journal of Applied Biomedicine
GeneticsMolecular BiologyPharmacologyBiochemistryBiological SciencesToxicologyMedicineAgriculturalNeurosciencePharmaceutics
2005English

Gene Expression-Based Prediction of Myeloma Cell Sensitivity to Histone Deacetylase Inhibitors

British Journal of Cancer
Cancer ResearchOncology
2013English

The Short-Term Effect of Histone Deacetylase�inhibitors, Chidamide and Valproic Acid, On�the�NF‑κB�pathway in Multiple Myeloma Cells

International Journal of Molecular Medicine
MedicineGenetics
2018English

Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi

Frontiers in Oncology
Cancer ResearchOncology
2018English

The Therapeutic Potential of Cell Cycle Targeting in Multiple Myeloma

Oncotarget
Oncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy